Phaseline

Targets › PD-L1

PD-L1: drug programs, companies and trials

5 programs from 5 companies in 6 trials: 5 Phase 2, 1 Phase 3; Oncology, Gastroenterology; next expected readout Nov 2026.

Open in Phaseline: the race on PD-L1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Shandong Cancer Hospital and InstituteTuvonralimab
PD-L1 inhibitor
PD-L1Phase 3Local Advanced Rectal Cancer; Rectal Malignant NeoplasmsNov 2026
Jiangxi Provincial Cancer HospitalTQB2450
PD-L1 inhibitor antibody
PD-L1Phase 2Esophageal Squamous Cell CarcinomaNov 2026
Cancer Institute and Hospital, Chinese Academy of Medical SciencesCardonilizumab
PD-L1 inhibitor
PD-L1Phase 2Esophageal CancerDec 2026
The First Affiliated Hospital with Nanjing Medical UniversityBemosubaiabimab
Anti-PD-L1 monoclonal antibody
PD-L1Phase 2Esophageal CancerApr 2028
First Affiliated Hospital of Zhejiang UniversityTuvonralimab
PD-L1 inhibitor
PD-L1Phase 2Locally Advanced Rectal Cancer (LARC)Dec 2029

Conditions

Esophageal Cancer (2) Local Advanced Rectal Cancer (1) Rectal Malignant Neoplasms (1) Esophageal Squamous Cell Carcinoma (1) Locally Advanced Rectal Cancer (LARC) (1)

Modalities

small molecule (3), antibody (1)

Companies

Shandong Cancer Hospital and Institute (1) Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) Jiangxi Provincial Cancer Hospital (1) The First Affiliated Hospital with Nanjing Medical University (1) First Affiliated Hospital of Zhejiang University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.